<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Pregabalin" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Pregabalin</book-part-id>
      <title-group>
        <title>Pregabalin</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Prazosin" document-type="chapter">Prazosin</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Pretomanid" document-type="chapter">Pretomanid</related-object>
    </book-part-meta>
    <body>
      <sec id="Pregabalin.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Pregabalin.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Pregabalin is an inhibitor of neuronal activity used for therapy of painful neuropathy and as an anticonvulsant. Therapy with pregabalin is not associated with serum aminotransferase elevations, and clinically apparent liver injury from pregabalin has been reported but appears to be quite rare.</p>
        </sec>
        <sec id="Pregabalin.Background">
          <title>Background</title>
          <p>Pregabalin (pre gab' a lin) is a structural analogue of gamma-aminobutyric acid (GABA) but is novel in its activity, having no effects on GABA-A or GABA-B receptors. Instead, the neuronal activity of pregabalin appears to be mediated by its binding to the alpha-2-delta subunit of the presynaptic voltage-gated calcium channel which leads to a decrease in release of neuroexcitatory neurotransmitters by hyperexcited neurons. Pregabalin has been shown to be effective in reducing neuropathic pain from diabetic and postherpetic neuropathy and is an effective anticonvulsant. Pregabalin was approved for use in the United States in 2004. Current indications include diabetic and post-herpetic neuropathy and as adjunctive therapy of partial onset seizures. Pregabalin is also used for fibromyalgia and off-label for generalized anxiety disorders and migraine. Pregabalin is available in capsules in varying concentrations from 25 to 300 mg under the brand name of Lyrica. The recommended initial dose for neuropathic pain is 50 to 75 mg two to three times daily, the maximum dose being 300 mg daily. Higher doses are used in treating seizures. The dose should be increased and tapered gradually. The most common side effects of pregabalin are dose related and include peripheral edema, weight gain, dizziness, somnolence, confusion, headache, blurred vision, tremor and ataxia. Rare but potentially severe adverse events include depression, suicidal ideation and behaviors, angioedema, and hypersensitivity reactions.</p>
        </sec>
        <sec id="Pregabalin.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Limited data is available on the hepatotoxicity of pregabalin. In prelicensure clinical trials in diabetic neuropathy and epilepsy, therapy with pregabalin was not associated with an increased frequency of serum aminotransferase elevations or liver toxicity. Since its approval and more wide scale use, however, pregabalin has been linked to rare instances of clinically apparent liver injury. Most cases were mild and frequently without jaundice. The latency to onset of injury was short, symptoms of liver injury arising within 3 to 14 days. Both cholestatic and hepatocellular patterns of injury have been reported. Signs of hypersensitivity (fever, rash, eosinophilia) and autoimmunity were not present. Some cases have been severe and associated with marked jaundice and prolongation of the prothrombin time, but all cases ultimately resolved after the medication was stopped without evidence of residual injury.</p>
          <p>Likelihood score: C (probable rare cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Pregabalin.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The low rate of significant hepatotoxicity from pregabalin may be due to its minimal hepatic metabolism and rapid urinary excretion. The injury is clearly idiosyncratic and either immunologic or metabolic causes are possible.</p>
        </sec>
        <sec id="Pregabalin.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The case reports of hepatic injury due to pregabalin were followed by complete recovery without evidence of residual or chronic injury. There is no information about cross reactivity with other compounds having similar structure (gabapentin).</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="Anticonvulsants" document-type="chapter">Anticonvulsants</related-object></p>
        </sec>
      </sec>
      <sec id="Pregabalin.CASE_REPORT">
        <title>CASE REPORT</title>
        <sec id="Pregabalin.Case_1_Mild_cholestatic_hepat">
          <title>Case 1. Mild cholestatic hepatitis attributed to pregabalin therapy.(<xref ref-type="bibr" rid="Pregabalin.REF.1">1</xref>)</title>
          <p>A 61 year old man underwent laminectomy for spinal stenosis and was started on pregabalin 2 weeks later. Within 2 days he developed dizziness, blurred vision, somnolence and fatigue, which worsened when the dose was increased from 75 to 150 mg/day one week later. Because of persistence of symptoms, blood tests were taken 11 days after starting therapy which revealed moderate enzyme elevations (Table). The patient had a history of hypertension and gout for which he took amlodipine (5 mg/day), candesartan (16 mg/day) and allopurinol (100 mg/day) chronically. Before the laminectomy, serum enzymes were tested and were normal. After surgery, he received metamizole (an NSAID not available in the US) for five days. Physical examination showed no jaundice, rash or signs of chronic liver disease. Tests for hepatitis A, B, C, D, and E, for HIV and for autoantibodies were negative. Abdominal ultrasound and MRCP were normal. Pregabalin was stopped and all symptoms except for mild fatigue, resolved rapidly. Reintroduction of pregabalin a few days later led to an immediate return of symptoms, but blood tests were not taken during the rechallenge. The abnormal enzyme values rapidly improved once pregabalin was stopped and were normal two months later.</p>
          <sec id="Pregabalin.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Pregabalin.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Pregabalin.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Pregabalin.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Pregabalin (75&#x02192;150 mg daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pregabalin.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Pregabalin.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Mixed (R=2.1)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pregabalin.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Pregabalin.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">1+ (enzyme elevations without jaundice)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pregabalin.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Pregabalin.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">2 days to onset of symptoms, 11 days to laboratory abnormalities</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pregabalin.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Pregabalin.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">Rapid (2 to 8 weeks)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Pregabalin.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Pregabalin.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Amlodipine, candesartan, and allopurinol chronically; metamizole for 5 days 3 weeks before onset.</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Pregabalin.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Pregabalin.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Pregabalin.Td_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Pregabalin.Td_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Pregabalin.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Pregabalin.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Pregabalin.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin<break/>(mg/dL)</th>
                    <th id="hd_h_Pregabalin.Td_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Preoperative evaluation</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_2 hd_h_Pregabalin.Td_1_1_1_3 hd_h_Pregabalin.Td_1_1_1_4 hd_h_Pregabalin.Td_1_1_1_5 hd_h_Pregabalin.Td_1_1_1_6" colspan="5" valign="top" align="center" rowspan="1">Pregabalin started: 75 mg/day increasing to 150 mg/day one week later</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">11 days</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">307</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">476</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.7</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">GGT 1546 U/L</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">22 days</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">10 days</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">37</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">174</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">1.0</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">GGT 542 U/L</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">11 weeks</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">10 weeks</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">32</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">125</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.9</td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">GGT 44 U/L</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_1 hd_h_Pregabalin.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
                      <bold>Normal Values</bold>
                    </td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;40</bold>
                    </td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;130</bold>
                    </td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;1.2</bold>
                    </td>
                    <td headers="hd_h_Pregabalin.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Pregabalin.Comment">
            <title>Comment</title>
            <p>Other causes of acute liver disease were excluded. The rechallenge was somewhat convincing, but the role of pregabalin in causing liver injury was not completely proven because of the lack of testing immediately before and after the two day rechallenge (on days 13-14 after starting). Based on the &#x0201c;R&#x0201d; value, the pattern of enzyme elevations was &#x0201c;mixed,&#x0201d; but the subsequent values and GGT elevations suggest that the injury was cholestatic. Most published cases of liver injury attributed to pregabalin have been marked by a short latency (3 to 14 days) and a rapidly resolving, self-limiting course.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Pregabalin.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Pregabalin &#x02013; Generic, Lyrica&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Anticonvulsants</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Pregabalin">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Pregabalin.CHEMICAL_FORMULA_AND_STRUCTUR">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Pregabalin.Te" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Pregabalin.Te_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Pregabalin.Te_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO</th>
                <th id="hd_h_Pregabalin.Te_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Pregabalin.Te_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Pregabalin.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pregabalin</td>
                <td headers="hd_h_Pregabalin.Te_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135081614">148553-50-8</ext-link>
                </td>
                <td headers="hd_h_Pregabalin.Te_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C8-H17-N-O2</td>
                <td headers="hd_h_Pregabalin.Te_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135081614" document-id-type="sid" document-type="summary" object-id="135081614" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Pregabalin.CITED_REFERENCE">
        <title>CITED REFERENCE</title>
        <ref-list id="Pregabalin.CITED_REFERENCE.reflist0">
          <ref id="Pregabalin.REF.1">
            <label>1</label>
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Crespo P&#x000e9;rez</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Moreira Vicente</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Manzano Fern&#x000e1;ndez</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Garc&#x000ed;a Aguilera</surname>
                  <given-names>XA</given-names>
                </name>
              </person-group>
              <comment>[Cholestasis associated with pregabalin treatment]</comment>
              <source>Med Clin (Barc)</source>
              <year>2008</year>
              <volume>130</volume>
              <fpage>157</fpage>
              <lpage>8</lpage>
              <comment>Spanish.</comment>
              <pub-id pub-id-type="pmid">18279637</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Pregabalin.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 30 July 2020</p>
        <p>Abbreviations used: DRESS, drug rash with eosinophilia and systemic symptoms; SJS/TEN, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
        <ref-list id="Pregabalin.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Pregabalin.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Anticonvulsants. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 498-516.<annotation><p><italic toggle="yes">(Expert review of liver injury due to anticonvulsants published in 1999, before the clinical availability of pregabalin which is not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pregabalin.REF.pirmohamed.2013">
            <mixed-citation publication-type="book">Pirmohamed M, Leeder SJ. Anticonvulsant agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013: pp 423-41.<annotation><p><italic toggle="yes">(Review of anticonvulsant induced liver injury does not specifically discuss pregabalin).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pregabalin.REF.smith.2018">
            <mixed-citation publication-type="book">Smith MD, Metcalf CS, Wilcox KS. Pharmacology of the epilepsies. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 303-26.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pregabalin.REF.huckle.2004.82">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Huckle</surname>
                  <given-names>R.</given-names>
                </name>
              </person-group>
              <article-title>Pregabalin (Pfizer).</article-title>
              <source>Curr Opin Investig Drugs</source>
              <year>2004</year>
              <volume>5</volume>
              <fpage>82</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(History of development of pregabalin and summary of information on mechanisms of action, pharmacology, pharmacokinetics, and clinical data supporting indications; no information on liver adverse events).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">14983979</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.benmenachem.2004.13">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ben-Menachem</surname>
                  <given-names>E.</given-names>
                </name>
              </person-group>
              <article-title>Pregabalin pharmacology and its relevance to clinical practice.</article-title>
              <source>Epilepsia</source>
              <year>2004</year>
              <volume>45</volume>
              <supplement>Suppl 6</supplement>
              <fpage>13</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Summary of pharmacology and pharmacokinetics of pregabalin; it has no hepatic metabolism and does not induce P450 enzymes).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15315511</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.kavoussi.2006.s128">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kavoussi</surname>
                  <given-names>R.</given-names>
                </name>
              </person-group>
              <article-title>Pregabalin: From molecule to medicine.</article-title>
              <source>Eur Neuropsychopharmacol</source>
              <year>2006</year>
              <volume>16</volume>
              <supplement>Suppl 2</supplement>
              <fpage>S128</fpage>
              <lpage>33</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Summary of mechanism of action and clinical experience with pregabalin in generalized anxiety disorder; no mention of hepatic adverse events).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16765030</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.tassone.2007.26">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Tassone</surname>
                  <given-names>DM</given-names>
                </name>
                <name name-style="western">
                  <surname>Boyce</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Guyer</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Nuzum</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <article-title>Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.</article-title>
              <source>Clin Ther</source>
              <year>2007</year>
              <volume>29</volume>
              <fpage>26</fpage>
              <lpage>48</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of efficacy and safety of pregabalin; major side effects were CNS related including dizziness, somnolence, headache, and ataxia, also edema and weight gain; withdrawal symptoms included anxiety, irritability and nervousness: &#x0201c;&#x02026;there were no significant differences in changes in blood chemistry or hematology tests&#x02026;&#x0201d;).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17379045</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.crespo_p_rez.2008.157">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Crespo P&#x000e9;rez</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Moreira Vicente</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Manzano Fern&#x000e1;ndez</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Garc&#x000ed;a Aguilera</surname>
                  <given-names>XA</given-names>
                </name>
              </person-group>
              <comment>[Cholestasis associated with pregabalin treatment]</comment>
              <source>Med Clin (Barc)</source>
              <year>2008</year>
              <volume>130</volume>
              <fpage>157</fpage>
              <lpage>8</lpage>
              <comment>Spanish.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(61 year old man with neuropathic pain after laminectomy developed symptoms of dizziness and fatigue within 2 days, and liver test abnormalities at 11 days after starting pregabalin [bilirubin 1.2 mg/dL, ALT 307 U/L, Alk P 476 U/L], symptoms recurring with rechallenge, and all signs of injury resolving within 2 months of stopping: Case 1).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18279637</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.einarsdottir.2008.1049">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Einarsdottir</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>E</given-names>
                </name>
              </person-group>
              <article-title>Pregabalin as a probable cause of acute liver injury.</article-title>
              <source>Eur J Gastroenterol Hepatol</source>
              <year>2008</year>
              <volume>20</volume>
              <fpage>1049</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(61 year old man developed nausea followed by jaundice 8 days after starting pregabalin [bilirubin 10.7 mg/dL, ALT 35 times ULN, INR 3.8], resolving completely within 24 weeks).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18787478</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.freeman.2008.1448">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Freeman</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Durso-Decruz</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Emir</surname>
                  <given-names>B</given-names>
                </name>
              </person-group>
              <article-title>Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses.</article-title>
              <source>Diabetes Care</source>
              <year>2008</year>
              <volume>31</volume>
              <fpage>1448</fpage>
              <lpage>54</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Pooled data from 7 trials of pregabalin given for 5-13 weeks vs placebo in 1510 patients; common side effects were edema, weight gain, dizziness and somnolence with &#x0201c;&#x02026;no clinically meaningful changes in laboratory values from baseline.&#x0201d;).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18356405</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.stein.2008.422">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Stein</surname>
                  <given-names>DJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Baldwin</surname>
                  <given-names>DS</given-names>
                </name>
                <name name-style="western">
                  <surname>Baldinetti</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Mandel</surname>
                  <given-names>F</given-names>
                </name>
              </person-group>
              <article-title>Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies.</article-title>
              <source>Eur Neuropsychopharmacol</source>
              <year>2008</year>
              <volume>18</volume>
              <fpage>422</fpage>
              <lpage>30</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Pooled analysis in &#x0003e;1000 patients with generalized anxiety disorder showed improvement with higher doses, but provided no information on tolerance or side effects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18359203</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>PB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davern</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Serrano</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochon</surname>
                  <given-names>J</given-names>
                </name>
                <collab>Drug Induced Liver Injury Network (DILIN)</collab>
              </person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, none were linked to pregabalin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF14">
            <mixed-citation publication-type="other">[Hepatic adverse effects of pregabalin (Lyrica)]. Lakartidningen 2010; 107(4): 194. Swedish.</mixed-citation>
          </ref>
          <ref id="Pregabalin.REF.johannessen_landmark.2010.119">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Johannessen Landmark</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Patsalos</surname>
                  <given-names>PN</given-names>
                </name>
              </person-group>
              <article-title>Drug interactions involving the new second- and third-generation antiepileptic drugs.</article-title>
              <source>Expert Rev Neurother</source>
              <year>2010</year>
              <volume>10</volume>
              <fpage>119</fpage>
              <lpage>40</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of drug-drug interactions; pregabalin has not been implicated in clinical significant drug interactions with other major anticonvulsants).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20021326</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.do_an.2011.628">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Do&#x0011f;an</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Ozberk</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Yurci</surname>
                  <given-names>A.</given-names>
                </name>
              </person-group>
              <article-title>Pregabalin-induced hepatotoxicity.</article-title>
              <source>Eur J Gastroenterol Hepatol</source>
              <year>2011</year>
              <volume>23</volume>
              <fpage>628</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(28 year old woman developed jaundice 4 months after starting pregabalin [bilirubin 16.3 mg/dL, ALT 26 times ULN, INR 1.91], resolving within 2 months of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21654262</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.sendra.2011.e32">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sendra</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Junyent</surname>
                  <given-names>TT</given-names>
                </name>
                <name name-style="western">
                  <surname>Pellicer</surname>
                  <given-names>MJ</given-names>
                </name>
              </person-group>
              <article-title>Pregabalin-induced hepatotoxicity.</article-title>
              <source>Ann Pharmacother</source>
              <year>2011</year>
              <volume>45</volume>
              <elocation-id>e32</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(59 year old man developed serum enzyme elevations 14 days after starting pregabalin [bilirubin 1.3 mg/dL, ALT 1582 U/L, Alk P 488 U/L], resolving in 4 months; patient had preexisting abnormalities and also received levofloxacin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21652790</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.zaccara.2011.826">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Zaccara</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Gangemi</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Perucca</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Specchio</surname>
                  <given-names>L</given-names>
                </name>
              </person-group>
              <article-title>The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.</article-title>
              <source>Epilepsia</source>
              <year>2011</year>
              <volume>52</volume>
              <fpage>826</fpage>
              <lpage>36</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of 38 double-blind trials of pregabalin identified 20 adverse events that were more common with pregabalin than comparator arms and were mostly dizziness, vertigo, ataxia, diplopia, tremor, somnolence and confusion; even in non-frequently mentioned side effects, ALT elevations and hepatotoxicity were not listed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21320112</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.toth.2012.487">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Toth</surname>
                  <given-names>C.</given-names>
                </name>
              </person-group>
              <article-title>Drug safety evaluation of pregabalin.</article-title>
              <source>Expert Opin Drug Saf</source>
              <year>2012</year>
              <volume>11</volume>
              <fpage>487</fpage>
              <lpage>502</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of structure, mechanism of action, pharmacokinetics, clinical uses and safety of pregabalin; common side effects include dizziness, sedation, dry mouth, weight gain and edema, rash and hypersensitivity reactions are rare; no mention of hepatotoxicity or ALT changes during therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22468635</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF20">
            <element-citation publication-type="journal">
              <article-title>Drugs for epilepsy.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2013</year>
              <volume>11</volume>
              <fpage>9</fpage>
              <lpage>18</lpage>
              <comment>Erratum in Treat Guidel Med Lett 2013; 11: 112</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise review of the drugs of choice for epilepsy; pregabalin is listed as an alternate drug of choice for partial onset seizures; side effects include somnolence, dizziness, ataxia, confusion, weight gain, dry mouth, blurred vision and edema; ALT elevations and liver injury are not mentioned).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23348233</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.bamanikar.2013.522">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bamanikar</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Dhobale</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Lokwani</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Pregabalin hypersensitivity in a patient treated for postherpetic neuralgia.</article-title>
              <source>Indian J Pharmacol</source>
              <year>2013</year>
              <volume>45</volume>
              <fpage>522</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(40 year old man developed fever, rash and facial swelling 2 weeks after starting pregabalin for post-herpetic neuralgia [bilirubin normal, ALT 250 U/L, Alk P normal], resolving on oral prednisolone and within a few months of stopping pregabalin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24130391</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Bergmann</surname>
                  <given-names>OM</given-names>
                </name>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>HK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kvaran</surname>
                  <given-names>RB</given-names>
                </name>
                <name name-style="western">
                  <surname>Olafsson</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, one of which was attributed to gabapentin but none to pregabalin ).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, 7 [4%] of which were attributed to anticonvulsants including phenytoin, carbamazepine and valproate but not pregabalin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.devarbhavi.2014.145">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Devarbhavi</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Andrade</surname>
                  <given-names>RJ</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs.</article-title>
              <source>Semin Liver Dis</source>
              <year>2014</year>
              <volume>34</volume>
              <fpage>145</fpage>
              <lpage>61</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of drug induced liver injury caused by several drug classes including antiepileptics, which account for 2-11% of all cases in various registries; a common presentation was with DRESS particularly with the older agents such as carbamazepine, phenytoin and phenobarbital and often associated with reactivation of human herpes virus 6 or 7).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24879980</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 40 [4.5%] were due to anticonvulsants including 3 attributed to gabapentin but only one to pregabalin; a 44 year old woman developed nausea followed by jaundice a week after starting pregabalin for peripheral neuropathy [bilirubin 16.9 mg/dL, ALT 229 U/L, Alk P 116 U/L], resolving slowly with stopping, but taking several other potential hepatotoxic agents such as mercaptopurine and simvastatin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.vidaurre.2017.23">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Vidaurre</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Gedela</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Yarosz</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Antiepileptic drugs and liver disease.</article-title>
              <source>Pediatr Neurol</source>
              <year>2017</year>
              <volume>77</volume>
              <fpage>23</fpage>
              <lpage>36</lpage>
              <annotation>
                <p><italic toggle="yes">(Review of the use of anticonvulsants in patients with liver disease recommends use of agents that have little hepatic metabolism such as</italic>&#x000a0;<italic toggle="yes">levetiracetam</italic><italic toggle="yes">, lacosamide, topiramate, gabapentin and pregabalin,</italic>&#x000a0;<italic toggle="yes">levetiracetam</italic>&#x000a0;<italic toggle="yes">being an "ideal" first line therapy for patients with liver disease because of its safety and lack of pharmacokinetic interactions).</italic></p>
              </annotation>
              <pub-id pub-id-type="pmid">29097018</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF27">
            <element-citation publication-type="journal">
              <article-title>Drugs for epilepsy.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2017</year>
              <volume>59</volume>
              <issue>1526</issue>
              <fpage>121</fpage>
              <lpage>30</lpage>
              <annotation>
                <p><italic toggle="yes">(Concise review of the drugs available for therapy of epilepsy lists</italic>&#x000a0;<italic toggle="yes">pregabalin as an adjunctive treatment for partial seizures similar in action and efficacy to gabapentin, its most common adverse events being somnolence, dizziness, ataxia, dry mouth, blurred vision, confusion, edema, weight gain and myoclonus; no mention of ALT elevations or hepatotoxicity</italic><italic toggle="yes">).</italic></p>
              </annotation>
              <pub-id pub-id-type="pmid">28746301</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.borrelli.2018.2318">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Borrelli</surname>
                  <given-names>EP</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>EY</given-names>
                </name>
                <name name-style="western">
                  <surname>Descoteaux</surname>
                  <given-names>AM</given-names>
                </name>
                <name name-style="western">
                  <surname>Kogut</surname>
                  <given-names>SJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Caffrey</surname>
                  <given-names>AR</given-names>
                </name>
              </person-group>
              <article-title>Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.</article-title>
              <source>Epilepsia</source>
              <year>2018</year>
              <volume>59</volume>
              <fpage>2318</fpage>
              <lpage>24</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of adverse event reports to the FDA between 2014 and 2018 identified ~2.9 million reports, 1034 for SJS/TEN, the most common class of drugs being anticonvulsants with 17 of 34 having at least one report, those most frequently linked being lamotrigine [n=106], carbamazepine [22], levetiracetam [14], phenytoin [14], valproate [9], clonazepam [8], zonisamide [7], gabapentin [4] and pregabalin [4]; no mention of accompanying liver injury or whether attribution was as a single agent or one of several).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30395352</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.canopaniagua.2019.501">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Cano-Paniagua</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Amariles</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Angulo</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Restrepo-Garay</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Epidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessment.</article-title>
              <source>Ann Hepatol</source>
              <year>2019</year>
              <volume>18</volume>
              <fpage>501</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 286 patients with liver test abnormalities seen in a single hospital in Colombia over a 1 year period, 17 were diagnosed with drug induced liver injury, the most common cause being antituberculosis therapy [n=6] followed by anticonvulsants [n=3, 1 each due to phenytoin, gabapentin and valproate]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31053545</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF30">
            <element-citation publication-type="journal">
              <article-title>Gabapentin and pregabalin: hepatic and haematological toxicity.</article-title>
              <source>Prescrire Int</source>
              <year>2014</year>
              <volume>23</volume>
              <fpage>267</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among adverse event reports to a French pharmacovigilance registry between 1995 and 2010, there were 90 reports of liver injury attributed to gabapentin, 37 described as hepatitis and 1 with a fatal outcome; and 32 reports of liver injury attributed to pregabalin of which 2 were fatal; no details given).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25954794</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.kowar.2015.1759">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kowar</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Friedrich</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Jacobs</surname>
                  <given-names>AH</given-names>
                </name>
              </person-group>
              <article-title>Pregabalin als seltene Ursache einer Hepatopathie</article-title>
              <comment>[Pregabalin as a rare cause of liver disease]</comment>
              <source>Dtsch Med Wochenschr</source>
              <year>2015</year>
              <volume>140</volume>
              <fpage>1759</fpage>
              <lpage>60</lpage>
              <comment>German.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(76 year old woman developed jaundice 15 days after starting pregabalin for back pain [bilirubin 6.0 mg/dL, ALT 2030 U/L, Alk P 650 U/L], with recovery 1-3 months after stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">26583821</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.d_zenli.2017.1407">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>D&#x000fc;zenli</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Ata</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>K&#x000f6;sem</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Bayram &#x000c7;arli</surname>
                  <given-names>A.</given-names>
                </name>
              </person-group>
              <article-title>Pregabaline as a rare cause of hepatotoxicity.</article-title>
              <source>Pain Med</source>
              <year>2017</year>
              <volume>18</volume>
              <fpage>1407</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(78 year old woman with painful neuropathy developed fatigue with a few days of starting pregabalin [bilirubin 0.6 mg/dL, ALT 701 U/L, Alk P 260 U/L], with rapid improvement on stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28087846</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF33">
            <element-citation publication-type="journal">
              <article-title>Nonopioid drugs for pain.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2018</year>
              <volume>60</volume>
              <issue>1540</issue>
              <fpage>25</fpage>
              <lpage>32</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise review of nonopioid drugs that are used for pain, mentions that pregabalin is approved for use in post-herpetic and diabetic neuropathy as well as for fibromyalgia; no mention of hepatic adverse events).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29422479</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.markman.2018.2815">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Markman</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Resnick</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Greenberg</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Katz</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Scavone</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Whalen</surname>
                  <given-names>E</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial.</article-title>
              <source>J Neurol</source>
              <year>2018</year>
              <volume>265</volume>
              <fpage>2815</fpage>
              <lpage>24</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 539 adults with post-traumatic neuropathic pain treated for 15 weeks with pregabalin or placebo, there were no differences in improvements in pain scores between the two groups while adverse events more common with pregabalin were dizziness [15% vs 4%] and somnolence [10% vs 3%]; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30242745</pub-id>
            </element-citation>
          </ref>
          <ref id="Pregabalin.REF.salehifar.2020.249">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Salehifar</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Janbabaei</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Hendouei</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Alipour</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Tabrizi</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Avan</surname>
                  <given-names>R</given-names>
                </name>
              </person-group>
              <article-title>Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial.</article-title>
              <source>Clin Drug Investig</source>
              <year>2020</year>
              <volume>40</volume>
              <fpage>249</fpage>
              <lpage>57</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 82 patients with post-taxane chemotherapy neuropathy treated with pregabalin or duloxetine for 6 weeks, response rates were 93% for pregabalin vs 38% for duloxetine and adverse events were mild-to-moderate, dizziness and somnolence more common with pregabalin, nausea and vomiting with duloxetine; no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31925721</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Pregabalin.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(pregabalin+AND+gamma-Aminobutyric+Acid/AE)+AND+Human%5BMH%5D+AND+(%20drug-induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%222009/11/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Pregabalin: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=pregabalin">Trials on Pregabalin: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
